Logo image of BU.CA

BURCON NUTRASCIENCE CORP (BU.CA) Stock Fundamental Analysis

Canada - TSX:BU - CA1208313009 - Common Stock

2.14 CAD
-0.06 (-2.73%)
Last: 10/3/2025, 7:00:00 PM
Fundamental Rating

2

BU gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 29 industry peers in the Chemicals industry. Both the profitability and financial health of BU have multiple concerns. BU is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BU has reported negative net income.
In the past year BU has reported a negative cash flow from operations.
BU had negative earnings in each of the past 5 years.
BU had a negative operating cash flow in each of the past 5 years.
BU.CA Yearly Net Income VS EBIT VS OCF VS FCFBU.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -36.62%, BU is doing worse than 78.57% of the companies in the same industry.
BU's Return On Equity of -274.39% is on the low side compared to the rest of the industry. BU is outperformed by 78.57% of its industry peers.
Industry RankSector Rank
ROA -36.62%
ROE -274.39%
ROIC N/A
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
BU.CA Yearly ROA, ROE, ROICBU.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400 -600

1.3 Margins

BU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BU.CA Yearly Profit, Operating, Gross MarginsBU.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

1

2. Health

2.1 Basic Checks

BU does not have a ROIC to compare to the WACC, probably because it is not profitable.
BU has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BU has been increased compared to 5 years ago.
Compared to 1 year ago, BU has a worse debt to assets ratio.
BU.CA Yearly Shares OutstandingBU.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
BU.CA Yearly Total Debt VS Total AssetsBU.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -7.77, we must say that BU is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.77, BU is doing worse than 75.00% of the companies in the same industry.
A Debt/Equity ratio of 5.27 is on the high side and indicates that BU has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 5.27, BU is doing worse than 78.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 5.27
Debt/FCF N/A
Altman-Z -7.77
ROIC/WACCN/A
WACC6.48%
BU.CA Yearly LT Debt VS Equity VS FCFBU.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.23 indicates that BU should not have too much problems paying its short term obligations.
With a Current ratio value of 1.23, BU is not doing good in the industry: 60.71% of the companies in the same industry are doing better.
BU has a Quick Ratio of 1.14. This is a normal value and indicates that BU is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.14, BU is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.14
BU.CA Yearly Current Assets VS Current LiabilitesBU.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

BU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1785.82%.
Looking at the last year, BU shows a quite strong growth in Revenue. The Revenue has grown by 16.90% in the last year.
BU shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 66.28% yearly.
EPS 1Y (TTM)-1785.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1868.65%
Revenue 1Y (TTM)16.9%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%46.68%

3.2 Future

BU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 224.01% yearly.
BU is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 228.16% yearly.
EPS Next Y-803.01%
EPS Next 2Y224.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year153.85%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BU.CA Yearly Revenue VS EstimatesBU.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M
BU.CA Yearly EPS VS EstimatesBU.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 -4 6 -6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BU. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 0.33, the valuation of BU can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BU indicates a rather cheap valuation: BU is cheaper than 100.00% of the companies listed in the same industry.
BU is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.32, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.33
BU.CA Price Earnings VS Forward Price EarningsBU.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BU.CA Per share dataBU.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as BU's earnings are expected to grow with 224.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y224.01%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BURCON NUTRASCIENCE CORP

TSX:BU (10/3/2025, 7:00:00 PM)

2.14

-0.06 (-2.73%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-12 2025-11-12
Inst Owners5.92%
Inst Owner ChangeN/A
Ins Owners30.89%
Ins Owner ChangeN/A
Market Cap27.16M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.67%
Min Revenue beat(2)-95.36%
Max Revenue beat(2)66.02%
Revenue beat(4)1
Avg Revenue beat(4)-52.8%
Min Revenue beat(4)-95.36%
Max Revenue beat(4)66.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2152.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-78.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-69.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.33
P/S 55.76
P/FCF N/A
P/OCF N/A
P/B 7.55
P/tB 11.59
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)6.58
Fwd EY307.56%
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.04
BVpS0.28
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.62%
ROE -274.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 5.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.61%
Cap/Sales 56.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.14
Altman-Z -7.77
F-Score2
WACC6.48%
ROIC/WACCN/A
Cap/Depr(3y)68.17%
Cap/Depr(5y)195.49%
Cap/Sales(3y)82.83%
Cap/Sales(5y)124.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1785.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1868.65%
EPS Next Y-803.01%
EPS Next 2Y224.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.9%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%46.68%
Revenue Next Year153.85%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.39%
OCF growth 3YN/A
OCF growth 5YN/A